HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Identification of glypican-3 as a novel tumor marker for melanoma.

AbstractPURPOSE:
We reported recently the novel tumor marker glypican-3 (GPC3) for hepatocellular carcinoma. In the present study, we investigated the expression of GPC3 in human melanoma cell lines and tissues and asked whether GPC3 could be a novel tumor marker for melanoma.
EXPERIMENTAL DESIGN:
Expression of GPC3 mRNA and protein was investigated in human melanoma cell lines and tissues using reverse transcription-PCR and immunohistochemical analysis. Secreted GPC3 protein was quantified using ELISA in culture supernatants of melanoma cell lines and in sera from 91 patients with melanoma and 28 disease-free patients after surgical removal of primary melanoma. All of the subjects were Japanese nationals.
RESULTS:
In >80% of melanoma and melanocytic nevus, there was evident expression of GPC3 mRNA and protein. Furthermore, GPC3 protein was evidenced in sera of 39.6% (36 of 91) of melanoma patients but not in sera from subjects with large congenital melanocytic nevus (0 of 5) and from healthy donors (0 of 60). Twenty-seven of 36 serum GPC3-positive patients were negative for both serum 5-S-cysteinyldopa and melanoma-inhibitory activity, well-known tumor markers for melanoma. The positive rate of serum GPC3 (39.6%) was significantly higher than that of 5-S-cysteinyldopa (26.7%) and of melanoma-inhibitory activity (20.9%). Surprisingly, we detected serum GPC3 even in patients with stage 0 in situ melanoma. The positive rate of serum GPC3 at stage 0, I, and II (44.4%, 40.0%, and 47.6%) was significantly higher than that of 5-S-cysteinyldopa (0.0%, 8.0%, and 10.0%). Also observed was the disappearance of GPC3 protein in sera from 11 patients after surgical removal of the melanoma.
CONCLUSIONS:
GPC3 is apparently a novel tumor marker useful for the diagnosis of melanoma, especially in early stages of the disorder.
AuthorsTetsuya Nakatsura, Toshiro Kageshita, Shosuke Ito, Kazumasa Wakamatsu, Mikio Monji, Yoshiaki Ikuta, Satoru Senju, Tomomichi Ono, Yasuharu Nishimura
JournalClinical cancer research : an official journal of the American Association for Cancer Research (Clin Cancer Res) Vol. 10 Issue 19 Pg. 6612-21 (Oct 01 2004) ISSN: 1078-0432 [Print] United States
PMID15475451 (Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Biomarkers, Tumor
  • Glypicans
  • Heparan Sulfate Proteoglycans
  • RNA, Messenger
Topics
  • Adult
  • Aged
  • Aged, 80 and over
  • Animals
  • Biomarkers, Tumor (analysis, genetics)
  • Cell Line, Tumor
  • Female
  • Gene Expression Regulation, Neoplastic
  • Glypicans
  • Heparan Sulfate Proteoglycans (analysis, blood, genetics)
  • Humans
  • Immunohistochemistry
  • Male
  • Melanoma (genetics, metabolism, pathology)
  • Mice
  • Middle Aged
  • NIH 3T3 Cells
  • Neoplasm Staging
  • RNA, Messenger (genetics, metabolism)
  • Reverse Transcriptase Polymerase Chain Reaction

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: